Competitive Advantages:
Reduces cell proliferation, Decreases cell migration, Ameliorates potential side effects, A non-invasive surgical method.
Provided herein are methods of measuring Cl 9MC miRNA amount and/or expression in a post-natal cell and/or tissue. Provided herein are methods of measuring CpG methylation of the upstream C19MC miRNA promoter region in a post-natal cell and/or tissue. Also provided herein are methÂods of treating a cellInfantile hemangiomas (IHs) are common benign vascular tumors in childhood. Until recently, the role of miRNAs in the onset and progression of IH had never been investigated. Our scientists have recently shown a significant upregulation of the chromosome 19 miRNA cluster (C19MC) in IH specimens. Given the role of C19MC miRNAs in the regulation of cell proliferation, invasion, and differentiation, they hypothesize that temporal expression of C19MC plays a pivotal role in the onset of IH. The C19MC miRNA is regulated by genomic imprinting with only the paternal allele expressed in the placenta. In addition, its expression is epigenetically regulated by DNA methylation of an upstream CpG rich promoter region. The inventors have developed a novel assays that can measure the expression and/or CpG methylation of the upstream C19MC promoter region in post-natal tissue. In addition to this, they have also developed a novel method to treat IHs via a modified CRISPR/Cas 9 Synergistic Activation Mediator system which incloves an upregulated actin gRNA (guide RNA) sequence that targets and inhibits the overexpressed C19MC promoter region commonly found in IHs. In summary, the inventors provide a novel method of measuring increased C19MC microRNA found in IHs and a new approach for designing novel, targeted miRNA-based therapeutics for the treatment of IH and other vascular malformations.
Brochure
